- Lobbying
- Lobbying by Charley's Fund
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Donna Mullins | CoS/Approps Staff, Rep. Frelinghuysen and Rep. Dean Gallo |
Robert Zucker | LD, Rep. Rothman; LA,Rep. Evans (IL); Sen. Lautenberg |
Charla Penn McManus | LA, Rep. Pascrell; SA/LC/LA, Rep. Boyd |
Chelsey Penrod Hickman | CoS, Rep. Kay Granger; LA Sen. Larry Craig |
Molly McDonnell | LC/LA/Senior Health Policy Advisor; Congressman Leonard Lance |
Scott Mackenzie | n/a |
Chelsey Hickman | n/a |
Charla Penn McManus | n/a |
Chelsey Penrod Hickman | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q2 Report
Q1 Report
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Amendment
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Medical
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Medical
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Registration
Issue(s) they said they’d lobby about: Implementation of the accelrated approval provisions of FDASIA as it pertains to treatments applicable for rare, deadly childhood deseases..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate